The clinical relevance of filaggrin mutations

Annals of Allergy, Asthma & Immunology

November 2016 Volume 117, Issue 5, Pages 483-489  CME Review

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planning Committee Members:
Mark W. Tenn, MD, BHSc (Author)
Anne K. Ellis, MD, MSc, FRCPC (Author)
Jonathan A. Bernstein, MD (CME Subcommittee)
Guha Krishnaswamy, MD (CME Subcommittee)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:
Describe the role of filaggrin in the maintenance of skin barrier function
Discuss how filaggrin null mutations can augment the risk of developing allergic diseases

Additional information
Disclosure: 

M.W. Tenn has nothing to disclose; A.E. Ellis has received research grants from AstraZeneca, Circassia Ltd, Merck, Novartis, Pfizer and SunPharma Advanced Research Corporation; M.H. Grayson has received research grants from Children’s Research Institute/Children’s Hospital of Wisconsin, Merck, National Institutes of Health (NIH), and Polyphor; G.D. Marshall has received research grants from Amgen, AstraZeneca, Health Resources and Services Administration (HRSA) and National Institutes of Health (NIH). J.J. Oppenheimer has been a consultant/advisor from GlaxoSmithKline, Meda, Mylan, and Teva; has received research grants from AstraZeneca, Bristol-Myers Squibb, Genentech, InterMune,  Novartis and Sunovio; J.A. Bernstein, and G. Krishnaswamy have no relevant financial relationships to disclose. Reviewers and Education/Editorial staff have no relevant financial relationships to disclose. Any unapproved/investigative uses of therapeutic agents/devices discussed are appropriately noted.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
11/01/2016
Course expires: 
10/31/2018
Cost:
$0.00
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Accreditation Period

Course opens: 
11/01/2016
Course expires: 
10/31/2018

Price

Cost:
$0.00
Please login or create an account to take this course.